Alcohol
Volume 21, Issue 2 , Pages 161-168 , June 2000

Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal

Received 3 November 1999 ,Revised 31 January 2000 ,Accepted 2 February 2000.

References 

  1. Adinoff B. Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcohol: Clin Exp Res. 1994;18:873–878
  2. Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology. 1997;131:123–129
  3. Ballenger JC. Psychopharmacology of the anxiety disorders. Psychiatr Clin North Am. 1984;7:757–771
  4. Ballenger JC, McDonald S, Noyes R, Rickels K, Sussman N, Woods S, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112–119) in generalized anxiety disorder. Psychopharmacol Bull. 1991;27:171–179
  5. Barker JL, McBurney RN, Mathers DA. Convulsant-induced depression of amino acid responses in cultured mouse spinal neurones studied under voltage clamp. Br J Pharmacol. 1983;80:619–629
  6. Benjamin D, Emmett-Oglesby MW, Lal H. Modulation of the discriminative stimulus produced by pentylenetetrazol by centrally administered drugs. Neuropharmacology. 1987;26:1727–1731
  7. Crabbe JC. Antagonism of ethanol withdrawal convulsions in withdrawal seizure prone mice by diazepam and abecarnil. Eur J Pharmacol. 1992;221:85–90
  8. Dawson GW, Jue SG, Brogden RN. Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs. 1984;27:132–147
  9. Deshpande Y, Longo WE, Chandel B, Niehoff M, Robinson S, Polities G, et al. Effect of platelet-activating factor and its antagonists on colonic dysmotility and tissue levels of colonic neuropeptides. Eur J Pharmacol. 1994;25:R1–R3
  10. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol. 1984;4:125–129
  11. Emmett-Oglesby MW, Lytle DA, English SA. Abecarnil used to treat benzodiazepine withdrawal. Psychopharmacol Ser. 1993;11:121–131
  12. Fabre LFJ, Gainey A, Kemple S. Pilot open-label study of alprazolam (U-31,889) in anxious alcoholic out-patients. J Intern Med Res. 1977;5:26–32
  13. Facklam M, Schoch P, Bonetti EP, Jenck F, Martin JR, Moreau JL, et al. Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther. 1992;261:1113–1121
  14. Fawcett JA, Kravitz HM. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. [Review] Pharmacotherapy. 1982;2:243–254
  15. File SE, Pellow S. The effects of triazolobenzodiazepines in two animal tests of anxiety and in the holeboard. Br J Pharmacol. 1985;86:729–735
  16. Gatch MB, Lal H. Pharmacological treatment of alcoholism. Prog Neuro-Psychopharmacol Biol Psychiatry. 1998;22:917–944
  17. Gatch MB, Wallis CJ, Lal H. The effects of adenosine ligands R-PIA and CPT on ethanol withdrawal. Alcohol. 1999;19:9–14
  18. Gatch MB, Wallis CJ, Lal H. Effects of NMDA receptor antagonists on ethanol withdrawal-induced anxiety in rats. Alcohol. 1999;19:207–211
  19. Gatch MB, Wallis CJ, Lal H. Effects of ritanserin on ethanol withdrawal induced anxiety in rats. Alcohol. 2000;21:11–17
  20. Gherezghiher T, Lal H. RO 15-1788 selectively reverses antagonism of pentylenetetrazol-induced discriminative stimuli by benzodiazepines but not by barbiturates. Life Sci. 1982;31:2955–2960
  21. Giusti P, Guidetti G, Costa E, Guidotti A. The preferential antagonism of pentylenetetrazole proconflict responses differentiates a class of anxiolytic benzodiazepines with potential antipanic action. J Pharmacol Exp Ther. 1991;257:1062–1068
  22. Goldstein DB. Relationship of alcohol dose to intensity of withdrawal signs in mice. J Pharmacol Exp Ther. 1972;180:203–215
  23. Griebel G, Sanger DJ, Perrault G. The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands. Psychopharmacology. 1996;124:245–254
  24. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV. Self-injection of barbiturates, benzodiazepines and other sedative–anxiolytics in baboons. Psychopharmacology. 1991;103:154–161
  25. Idemudia SO, Bhadra S, Lal H. The pentylenetetrazol-like interoceptive stimulus produced by ethanol withdrawal is potentiated by bicuculline and picrotoxinin. Neuropsychopharmacology. 1989;2:115–122
  26. Institute of Laboratory Animal Resources . Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996;
  27. Jaffe J, Kranzler H, Ciraulo D. Drugs used in the treatment of alcoholism. In:  Mendelson J,  Mello N editor. Medical Treatment and Diagnosis of Alcoholism. New York: McGraw-Hill; 1992;p. 421–461
  28. Johnston AL, File SE. Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety. Psychiatry Res. 1988;25:81–90
  29. Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ, Stephens DN. Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacology. 1994;114:191–199
  30. Jung, M.E. (1994). Discriminative and negative reinforcing properties of the periaqueductal gray and the medial hypothalamus. Master's Thesis. University of North Texas Health Science Center at Fort Worth.
  31. Kaminski DL, Feinstein WK, Deshpande YG. The production of experimental cholecystitis by endotoxin. Prostaglandins. 1994;47:233–245
  32. Kolin IS, Linet J. Double-blind comparison of alprazolam and diazepam for subchronic withdrawal from alcohol. J Clin Psychiat. 1981;42:169–173
  33. Lal H, Harris CM, Benjamin D, Springfield AC, Bhadra S, Emmett-Oglesby MW. Characterization of a pentylenetetrazol-like interoceptive stimulus produced by ethanol withdrawal. J Pharmacol Exp Ther. 1988;247:508–518
  34. Lal H, Prather PL, Rezazadeh SM. Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: reversal by buspirone. Alcohol. 1991;8:467–471
  35. Lal H, Prather PL, Rezazadeh SM. Potential role of 5HT1C and/or 5HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol: Clin Exp Res. 1993;17:411–417
  36. Lecci A, Borsini F, Volterra G, Meli A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology. 1990;101:255–261
  37. Linnoila MI. Anxiety and alcoholism. J Clin Psychiatry. 1989;50:26–29Suppl.
  38. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 1987;92:180–185
  39. Litten RZ, Allen JP. Pharmacotherapies for alcoholism: promising agents and clinical issues. Alcohol: Clin Exp Res. 1991;15:620–633
  40. Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1997;58:11–18Suppl.
  41. Pinna G, Galici R, Schneider HH, Stephens DN, Turski L. Alprazolam dependence prevented by substituting with the beta-carboline abecarnil. Proc Natl Acad Sci USA. 1997;94:2719–2723
  42. Prather PL, Lal H. Protracted withdrawal: sensitization of the anxiogenic response to cocaine in rats concurrently treated with ethanol. Neuropsychopharmacology. 1992;6:23–29
  43. Prather PL, Rezazadeh SM, Lal H. Mianserin in the treatment of ethanol withdrawal in the rat: prevention of behaviors indicative of anxiety. Psychopharmacol Bull. 1991;27:285–289
  44. Puia G, Santi MR, Vicini S, Pritchett DB, Seeburg PH, Costa E. Differences in the negative allosteric modulation of gamma-aminobutyric acid receptors elicited by 4′-chlorodiazepam and by a beta-carboline-3-carboxylate ester: a study with natural and reconstituted receptors. Proc Natl Acad Sci USA. 1989;86:7275–7279
  45. Puia G, Vicini S, Seeburg PH, Costa E. Influence of recombinant gamma-aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of gamma-aminobutyric acid-gated Cl− currents. Mol Pharmacol. 1991;39:691–696
  46. Rex AS, Rex DN, Fink H. “Anxiolytic” action of diazepam and abecarnil in a modified open field test. Pharmacol Biochem Behav. 1996;53:1005–1011
  47. Rezazadeh SM, Prather PL, Lal H. Sensitization to 5-HT1C receptor agonist in rats observed following withdrawal from chronic ethanol. Alcohol. 1993;10:281–283
  48. Rickels K, Csanalosi I, Greisman P, Cohen D, Werblowsky J, Ross HA, et al. A controlled clinical trial of alprazolam for the treatment of anxiety. Am J Psychiatry. 1983;140:82–85
  49. Rodriguez-Barbero A, Rodriguez-Lopez AM, Gonzalez-Sarmiento R, Lopez-Novoa JM. Gentamicin activates rat mesangial cells. A role for platelet activating factor. Kidney Int. 1995;47:1346–1353
  50. Roelofs SM. Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. Alcohol. 1985;2:501–505
  51. Rush CR, Higgins ST, Bickel WK, Hughes JR. Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review. [Review] Neurosci Biobehav Rev. 1993;17:277–285
  52. Sannerud CA, Ator NA, Griffiths RR. Behavioral pharmacology of abecarnil in baboons: reduced dependence and abuse potential. Psychopharmacol Ser. 1993;11:113–120
  53. Serra M, Ghiani CA, Maciocco E, Pisu MG, Tuligi G, Porceddu ML, et al. Failure of chronic treatment with abecarnil to induce contingent and noncontingent tolerance in pentylenetetrazol-kindled rats. Epilepsia. 1996;37:332–335
  54. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. [Review] N Engl J Med. 1993;328:1398–1405
  55. Shearman G, Lal H. Discriminative stimulus properties of pentylenetetrazol and bemegride: some generalization and antagonism tests. Psychopharmacology. 1979;64:315–319
  56. Shearman GT, Lal H. Generalization and antagonism studies with convulsant, GABAergic and anticonvulsant drugs in rats trained to discriminate pentylenetetrazol from saline. Neuropharmacology. 1980;19:473–479
  57. Shearman GT, Miksic S, Lal H. Lack of tolerance development to benzodiazepines in antagonism of the pentylenetetrazol discriminative stimulus. Pharmacol Biochem Behav. 1979;10:795–797
  58. Stephens DN, Schneider HH, Kehr W, Andrews JS, Rettig KJ, Turski L, et al. Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther. 1990;253:334–343
  59. Stephens DN, Shearman GT, Kehr W. Discriminative stimulus properties of beta-carbolines characterized as agonists and inverse agonists at central benzodiazepine receptors. Psychopharmacology. 1984;83:233–239
  60. Steppuhn KG, Schneider HH, Turski L, Stephens DN. Long-term treatment with abecarnil does not induce diazepam-like dependence in mice. J Pharmacol Exp Ther. 1993;264:1395–1400
  61. Tubridy P. Alprazolam versus chlormethiazole in acute alcohol withdrawal. Br J Addict. 1988;83:581–585
  62. Turski L, Stephens DN, Jensen LH, Petersen EN, Meldrum BS, Patel S, et al. Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther. 1990;253:344–352
  63. Wallis CJ, Rezazadeh SM, Lal H. GM1 ganglioside reduces ethanol intoxication and the development of ethanol dependence. Alcohol. 1995;12:573–580
  64. Wilson J, Watson WP, Little HJ. CCK (B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze. Psychopharmacology. 1998;137:120–131

PII: S0741-8329(00)00079-3

Alcohol
Volume 21, Issue 2 , Pages 161-168 , June 2000

Article Tools

* Image Usage & Resolution